Penumbra Inc (PEN)

Currency in USD
329.89
-3.11(-0.93%)
Closed·
329.890.00(0.00%)
·
Earnings results expected in 9 days
PEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
329.62334.04
52 wk Range
221.26362.41
Key Statistics
Prev. Close
333
Open
332.48
Day's Range
329.62-334.04
52 wk Range
221.26-362.41
Volume
352.31K
Average Volume (3m)
713.05K
1-Year Change
10.6085%
Book Value / Share
36.45
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PEN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
365.79
Upside
+10.88%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility

Penumbra Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Penumbra Inc SWOT Analysis


Market Dominance
Penumbra's strong performance in the U.S. VTE market, with 42% year-over-year growth, signals potential for significant market share gains and expansion
Innovation Pipeline
Explore Penumbra's product developments, including Thunderbolt and Lightning Flash 2.0, poised to drive growth and solidify market position
Financial Outlook
Analysts project double-digit revenue growth and margin expansion, with price targets ranging from $232 to $330, reflecting optimism in Penumbra's prospects
Challenges Ahead
Delve into Penumbra's strategic approach to overcoming China market headwinds and potential operational hurdles while maintaining a conservative growth outlook
Read full SWOT analysis

Penumbra Inc Earnings Call Summary for Q3/2025

  • Penumbra reported Q3 2025 revenue of $354.7M, up 17.8% YoY, exceeding forecasts of $340.91M despite a 4.05% stock drop during regular trading.
  • U.S. revenue surged 21.5% YoY to $275M, while international revenue grew 6.6% to $79.7M; gross margin expanded 130 basis points to 67.8%.
  • The company raised full-year revenue guidance to $1,375-$1,380M and targets gross margin exceeding 70% by end of 2026.
  • CEO Adam Elsesser expressed confidence in long-term strategy, with upcoming Thunderbolt neurovascular product launch expected to drive future growth.
  • Storm PE trial demonstrated CABT superiority to standard care, reinforcing Penumbra's innovation leadership in thrombectomy treatments.
Last Updated: 2025-11-05, 06:12 p/m
Read Full Transcript

Compare PEN to Peers and Sector

Metrics to compare
PEN
Peers
Sector
Relationship
P/E Ratio
73.0x9.1x−0.4x
PEG Ratio
0.060.650.00
Price/Book
9.1x1.9x2.6x
Price / LTM Sales
9.2x1.8x3.2x
Upside (Analyst Target)
13.4%44.6%46.2%
Fair Value Upside
Unlock14.8%7.2%Unlock

Analyst Ratings

4 Buy
13 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 365.79
(+10.88% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Evercore ISI
Buy345.00+4.58%360.00MaintainApr 06, 2026
UBS
Hold374.00+13.37%374.00MaintainMar 17, 2026
UBS
Hold374.00+13.37%374.00MaintainFeb 26, 2026
Evercore ISI
Buy360.00+9.13%340.00MaintainFeb 25, 2026
RBC Capital
Hold374.00+13.37%-DowngradeJan 20, 2026

Earnings

Latest Release
Feb 25, 2026
EPS / Forecast
1.18 / 1.10
Revenue / Forecast
385.39M / 361.8M
EPS Revisions
Last 90 days

PEN Income Statement

People Also Watch

81.58
GGG
-0.73%
70.22
KRMN
-8.33%
101.98
EHC
+0.12%
33.44
BSY
+2.42%

FAQ

What Is the Penumbra Inc (PEN) Stock Price Today?

The Penumbra Inc stock price today is 329.89 USD.

What Stock Exchange Does Penumbra Inc Trade On?

Penumbra Inc is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Penumbra Inc?

The stock symbol for Penumbra Inc is "PEN."

What Is the Penumbra Inc Market Cap?

As of today, Penumbra Inc market cap is 12.97B USD.

What Is Penumbra Inc's Earnings Per Share (TTM)?

The Penumbra Inc EPS (TTM) is 4.52.

When Is the Next Penumbra Inc Earnings Date?

Penumbra Inc will release its next earnings report on May 05, 2026.

From a Technical Analysis Perspective, Is PEN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Penumbra Inc Stock Split?

Penumbra Inc has split 0 times.

How Many Employees Does Penumbra Inc Have?

Penumbra Inc has 4700 employees.

What is the current trading status of Penumbra Inc (PEN)?

As of Apr 26, 2026, Penumbra Inc (PEN) is trading at a price of 329.89 USD, with a previous close of 333.00 USD. The stock has fluctuated within a day range of 329.62 USD to 334.04 USD, while its 52-week range spans from 221.26 USD to 362.41 USD.

What Is Penumbra Inc (PEN) Price Target According to Analysts?

The average 12-month price target for Penumbra Inc is 365.79 USD, with a high estimate of 374 USD and a low estimate of 326 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +10.88% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.